AbbVie jumps as Q1 results drive raised 2026 profit outlook and key-drug momentum
AbbVie shares are rising after the company reported Q1 2026 results and lifted full-year adjusted EPS guidance to $14.08–$14.28 from $13.96–$14.16. The quarter showed strong growth in key drugs Skyrizi ($4.483B) and Rinvoq ($2.119B), helping offset continued Humira declines.
1. What’s moving the stock
AbbVie is climbing after releasing first-quarter 2026 financial results and increasing its full-year 2026 adjusted diluted EPS guidance range to $14.08–$14.28 (from $13.96–$14.16). The guidance raise is the key catalyst behind the move, signaling stronger profit expectations despite ongoing Humira erosion and continued investment spending. (news.abbvie.com)
2. The numbers investors are focusing on
For Q1 2026 (ended March 31, 2026), AbbVie reported worldwide net revenues of $15.002 billion (+12.4% reported, +10.3% operational) and adjusted diluted EPS of $2.65 (+7.7%). Growth was led by immunology and neuroscience, while Humira continued to decline. (news.abbvie.com)
3. Product drivers: Skyrizi and Rinvoq offset Humira declines
In immunology, Skyrizi delivered $4.483 billion in Q1 revenue and Rinvoq delivered $2.119 billion, while Humira fell to $688 million. Investors are interpreting the results as further confirmation that AbbVie’s post-Humira transition remains on track, with newer immunology products sustaining the company’s growth profile. (news.abbvie.com)
4. What to watch next
The market will monitor whether Skyrizi and Rinvoq can keep scaling through additional indications and competitive pressure, and whether higher acquired IPR&D and milestone expenses persist. Any further updates on business development activity and pipeline progress could add volatility in coming sessions as investors recalibrate 2026 profit expectations around the raised guidance range. (news.abbvie.com)